公开(公告)号：US20240173353A1

公开(公告)日：2024-05-30

申请号：US18550338

申请日：2022-03-16

申请人： SHANGHAI IASO BIOTECHNOLOGY CO., LTD.

发明人： Guang HU ,  Jiayuan ZHANG ,  Wenjing GAO ,  Wenjie DONG ,  Xiaomin YAO ,  Zhi LIU ,  Xiaoqian WANG

IPC分类号： A61K35/17 ,  A61K31/5025 ,  A61K31/506 ,  A61K39/00 ,  A61P37/04 ,  C12N5/0783 ,  C12N9/12 ,  C12N15/11 ,  C12N15/86

CPC分类号： A61K35/17 ,  A61K31/5025 ,  A61K31/506 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464454 ,  A61P37/04 ,  C12N5/0636 ,  C12N9/1205 ,  C12N15/11 ,  C12N15/86 ,  A61K2239/22 ,  A61K2239/26 ,  C12N2740/15043 ,  C12Y207/10002

摘要： A cell comprising a mutant protein, the mutant protein causing the cell to be insensitive toward an inhibitor which affects the activity and; or killing function thereof; a universal chimeric antigen receptor T cell which is related to the cell and which is suitable for administration to non-specific patients; and a method for preparing the described cells and an application of the cells in cell therapy.

公开(公告)号：US20240041868A1

公开(公告)日：2024-02-08

申请号：US18328364

申请日：2023-06-02

申请人： Pathways Neuro Pharma, Inc.

发明人： Warren C. LAU

IPC分类号： A61K31/497 ,  C12N9/12 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377

CPC分类号： A61K31/497 ,  C12N9/1205 ,  C12N9/12 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  C12Y207/10002 ,  C07K2319/23

摘要： The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.

公开(公告)号：US20240025970A1

公开(公告)日：2024-01-25

申请号：US18249237

申请日：2021-10-17

申请人： Sherwood Russ Lehrman ,  Ehud Goldin

发明人： Sherwood Russ Lehrman ,  Ehud Goldin

IPC分类号： C07K14/785 ,  A61K31/685 ,  A61K38/45 ,  A61K45/06 ,  A61K47/64 ,  A61K9/14 ,  A61P31/12 ,  A61P11/00

CPC分类号： C07K14/785 ,  A61K31/685 ,  A61K38/45 ,  A61K45/06 ,  A61K47/64 ,  A61K9/14 ,  A61P31/12 ,  A61P11/00 ,  C12Y207/10002

摘要： Described are heat stable protein-phospholipid concentrates within lung surfactant therapeutic compositions for the treatment of respiratory diseases in premature infants, children and adults. The concentrates can be suitable for localized delivery with improved transport to and spreadability within the lung and other tissues resulting in greater efficacy and efficiency of treatment.

公开(公告)号：US20180237797A1

公开(公告)日：2018-08-23

申请号：US15553530

申请日：2016-03-29

申请人： Jeffrey Thomas Loh

发明人： Jeffrey Thomas Loh

IPC分类号： C12N15/85 ,  A61K35/19 ,  A61K9/00 ,  C12N5/078 ,  C12N15/90 ,  C12N9/12 ,  C07K14/47 ,  C07K14/82

CPC分类号： C12N15/85 ,  A61K9/0019 ,  A61K35/19 ,  C07K14/4728 ,  C07K14/82 ,  C12N5/0644 ,  C12N5/0647 ,  C12N9/12 ,  C12N15/63 ,  C12N15/907 ,  C12N2501/145 ,  C12N2501/727 ,  C12N2506/11 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2521/00 ,  C12Y207/10002

摘要： The present invention encompasses methods for generating mutant janus kinase 2 (JAK-2), mutant calreticulin (CALR), or thrombopoietin receptor (MPL) modified megakaryocytes (modified MKs) expressing a mutant Janus kinase 2 peptide, a mutant calreticulin peptide, and/or a mutant thrombopoietin receptor peptide, JAK2-, CALR-, and/or MPL-modified platelets as a composition of matter, and methods for using the generated JAK2-, CALR-, and/or MPL-modified platelets.

公开(公告)号：US20180066327A1

公开(公告)日：2018-03-08

申请号：US15557740

申请日：2016-03-14

申请人： Joslin Diabetes Center, Inc.

发明人： George Liang King ,  Mogher Khamaisi ,  Hillary A. Keenan

IPC分类号： A61K35/33 ,  A61K35/36 ,  A61K35/545 ,  A61K38/10 ,  C12N15/113 ,  C12N5/077 ,  C12N15/52

CPC分类号： C12Y207/10002 ,  A61K35/33 ,  A61K35/36 ,  A61K35/545 ,  A61K38/10 ,  A61K38/1709 ,  A61K48/00 ,  C12N5/0656 ,  C12N15/1137 ,  C12N15/52 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2501/727

摘要： Methods of accelerating wound healing in diabetic subjects using autologous cell grafts treated to specifically inhibit Protein Kinase C delta (PKC6), as well as cells and compositions for use in these methods. Provided herein are methods for preparing cells for application to a wound in a diabetic subject. The methods include incubating the cells in the presence of an effective amount of a PKC6 inhibitor.

公开(公告)号：US20180030475A1

公开(公告)日：2018-02-01

申请号：US15553522

申请日：2016-03-29

申请人： Jeffrey Thomas LOH

发明人： Jeffrey Thomas LOH

IPC分类号： C12N15/85 ,  C12N15/63

CPC分类号： C12N15/85 ,  A61K9/0019 ,  A61K35/19 ,  C07K14/4728 ,  C07K14/82 ,  C12N5/0644 ,  C12N5/0647 ,  C12N9/12 ,  C12N15/63 ,  C12N15/907 ,  C12N2501/145 ,  C12N2501/727 ,  C12N2506/11 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2521/00 ,  C12Y207/10002

摘要： The present invention encompasses methods for generating JAK2-modified cultured red blood cells (modified cRBCs) expressing a mutant Janus kinase 2 peptide, JAK2-modified cRBCs as a composition of matter, and methods for using the generated JAK2-modified cRBCs.

公开(公告)号：US20170276688A1

公开(公告)日：2017-09-28

申请号：US15372906

申请日：2016-12-08

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： Roger A. Johns ,  Qingning Su ,  Hunter Clay Champion

IPC分类号： G01N33/68 ,  G01N33/74 ,  G01N33/543 ,  C07K16/40 ,  C07K14/47 ,  C07K16/18 ,  C12N9/12

CPC分类号： G01N33/6884 ,  A61K2039/505 ,  C07K14/4702 ,  C07K16/18 ,  C07K16/22 ,  C07K16/40 ,  C12N9/1205 ,  C12Y207/10002 ,  G01N33/54306 ,  G01N33/74 ,  G01N2333/47 ,  G01N2333/4703 ,  G01N2333/912 ,  G01N2500/02 ,  G01N2800/12 ,  G01N2800/122 ,  G01N2800/7038

摘要： Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. We also demonstrated that BTK and the closely related tyrosine kinase Fyn, colocalized at the growth cone process in these cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 minutes. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells, which was completely blocked by the BTK inhibitor, LFM-A13. In vivo studies, using the rat hindlimb ischemia model, revealed that HIMF can stimulate angiogenesis in the hypoxic tissue probably through inducing the migration of endothelial progenitor cells (EPCs) to areas of active angiogenesis. Our results indicate that HIMF may acts as a chemotactic molecule in stimulating the migration of leukocytes/EPCs from bone marrow to targeted tissues through activation of the BTK pathway.

公开(公告)号：US20170174789A1

公开(公告)日：2017-06-22

申请号：US15445563

申请日：2017-02-28

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Gavin Thurston

IPC分类号： C07K16/40 ,  C07K16/10 ,  C07K16/28

CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C12N9/12 ,  C12Y207/10002

摘要： The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis. In certain embodiments, pairs of activating Tie-2 antibodies showed an additive effect on the treatment of influenza infection when combined with anti-influenza HA. In other embodiments, prophylactic administration pairs of activating Tie2 antibodies delayed death and improved survival in a lethal model of E. coli intoxication (sepsis) over isotype/untreated controls.

公开(公告)号：US09675680B2

公开(公告)日：2017-06-13

申请号：US14924546

申请日：2015-10-27

申请人： Oncotherapy Science, Inc.

发明人： Takuya Tsunoda ,  Ryuji Ohsawa

IPC分类号： A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K7/06 ,  C12N5/0783 ,  C12N9/12

CPC分类号： A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K14/4747 ,  C12N5/0638 ,  C12N9/12 ,  C12N2502/11 ,  C12N2510/00 ,  C12Y207/10002 ,  C12Y207/11001

摘要： According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.

公开(公告)号：US20160250183A1

公开(公告)日：2016-09-01

申请号：US15148420

申请日：2016-05-06

申请人： Douglas V. Faller ,  Robert M. Williams

发明人： Douglas V. Faller ,  Robert M. Williams

IPC分类号： A61K31/403 ,  G01N33/50 ,  A61K9/00

CPC分类号： A61K31/403 ,  A61K9/0019 ,  A61K31/404 ,  A61K45/06 ,  A61P35/00 ,  C07D209/86 ,  C07D405/06 ,  C07D487/14 ,  C12Y207/10002 ,  G01N33/5011 ,  G01N2333/91205

摘要： The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.

摘要翻译： 本发明涉及作为PKCδ特异性抑制剂的化合物，以及用于治疗和预防癌症和其它病症的方法和组合物。 包含本发明化合物的组合物用于治疗癌症例如类癌和神经内分泌肿瘤，恶性黑素瘤，胰腺癌，胃肠癌和肺癌。 肺和胃肠道起源的神经内分泌肿瘤细胞系对本发明化合物对PKCδ抑制的惊人的敏感性。 本发明进一步涉及包含如图1和2中公开和描述的式（Ia），（IIa），（IIIa），（IVa）和（V）化合物的方法，组合物和试剂盒。 11和12。